BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marcelino Meliso F, Hubert CG, Favoretto Galante PA, Penalva LO. RNA processing as an alternative route to attack glioblastoma. Hum Genet 2017;136:1129-41. [PMID: 28608251 DOI: 10.1007/s00439-017-1819-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Chai RC, Li YM, Zhang KN, Chang YZ, Liu YQ, Zhao Z, Wang ZL, Chang YH, Li GZ, Wang KY, Wu F, Wang YZ. RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight 2019;5:130591. [PMID: 31408440 DOI: 10.1172/jci.insight.130591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
2 Coppin L, Leclerc J, Vincent A, Porchet N, Pigny P. Messenger RNA Life-Cycle in Cancer Cells: Emerging Role of Conventional and Non-Conventional RNA-Binding Proteins? Int J Mol Sci 2018;19:E650. [PMID: 29495341 DOI: 10.3390/ijms19030650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
3 Dymova MA, Kuligina EV, Richter VA. Molecular Mechanisms of Drug Resistance in Glioblastoma. Int J Mol Sci 2021;22:6385. [PMID: 34203727 DOI: 10.3390/ijms22126385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li Y, Guo D. Genome-wide profiling of alternative splicing in glioblastoma and their clinical value. BMC Cancer 2021;21:958. [PMID: 34445990 DOI: 10.1186/s12885-021-08681-z] [Reference Citation Analysis]
5 Wang Y, Zhang H, Jiao B, Nie J, Li X, Wang W, Wang H. The Roles of Alternative Splicing in Tumor-immune Cell Interactions. Curr Cancer Drug Targets 2020;20:729-40. [PMID: 32560607 DOI: 10.2174/1568009620666200619123725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wang BD, Lee NH. Aberrant RNA Splicing in Cancer and Drug Resistance. Cancers (Basel) 2018;10:E458. [PMID: 30463359 DOI: 10.3390/cancers10110458] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 18.3] [Reference Citation Analysis]
7 Rani AQM, Farea M, Maeta K, Kawaguchi T, Awano H, Nagai M, Nishio H, Matsuo M. Identification of the shortest splice variant of Dp71, together with five known variants, in glioblastoma cells. Biochemical and Biophysical Research Communications 2019;508:640-5. [DOI: 10.1016/j.bbrc.2018.11.168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 David JK, Maden SK, Weeder BR, Thompson RF, Nellore A. Putatively cancer-specific exon-exon junctions are shared across patients and present in developmental and other non-cancer cells. NAR Cancer 2020;2:zcaa001. [PMID: 34316681 DOI: 10.1093/narcan/zcaa001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. Cells 2021;10:484. [PMID: 33668200 DOI: 10.3390/cells10030484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Rätsch G; Cancer Genome Atlas Research Network. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell 2018;34:211-224.e6. [PMID: 30078747 DOI: 10.1016/j.ccell.2018.07.001] [Cited by in Crossref: 263] [Cited by in F6Publishing: 232] [Article Influence: 65.8] [Reference Citation Analysis]
11 Li Y, Ren Z, Peng Y, Li K, Wang X, Huang G, Qi S, Liu Y. Classification of glioma based on prognostic alternative splicing. BMC Med Genomics 2019;12:165. [PMID: 31729991 DOI: 10.1186/s12920-019-0603-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
12 Canbezdi C, Tarin M, Houy A, Bellanger D, Popova T, Stern MH, Roman-Roman S, Alsafadi S. Functional and conformational impact of cancer-associated SF3B1 mutations depends on the position and the charge of amino acid substitution. Comput Struct Biotechnol J 2021;19:1361-70. [PMID: 33777335 DOI: 10.1016/j.csbj.2021.02.012] [Reference Citation Analysis]
13 Conn VM, Gabryelska M, Marri S, Stringer BW, Ormsby RJ, Penn T, Poonnoose S, Kichenadasse G, Conn SJ. SRRM4 Expands the Repertoire of Circular RNAs by Regulating Microexon Inclusion. Cells 2020;9:E2488. [PMID: 33207694 DOI: 10.3390/cells9112488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sun X, Tian Y, Wang J, Sun Z, Zhu Y. Genome-wide analysis reveals the association between alternative splicing and DNA methylation across human solid tumors. BMC Med Genomics 2020;13:4. [PMID: 31906954 DOI: 10.1186/s12920-019-0654-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
15 Mahyoob Rani AQ, Maeta K, Kawaguchi T, Awano H, Nagai M, Nishio H, Matsuo M. Schwann cell-specific Dp116 is expressed in glioblastoma cells, revealing two novel DMD gene splicing patterns. Biochem Biophys Rep 2019;20:100703. [PMID: 31737793 DOI: 10.1016/j.bbrep.2019.100703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Chai RC, Wang N, Chang YZ, Zhang KN, Li JJ, Niu JJ, Wu F, Liu YQ, Wang YZ. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell Int 2019;19:155. [PMID: 31171919 DOI: 10.1186/s12935-019-0867-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
17 Reinhold WC, Varma S, Sunshine M, Elloumi F, Ofori-Atta K, Lee S, Trepel JB, Meltzer PS, Doroshow JH, Pommier Y. RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. Cancer Res 2019;79:3514-24. [PMID: 31113817 DOI: 10.1158/0008-5472.CAN-18-2047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
18 Jayaram S, Balakrishnan L, Singh M, Zabihi A, Ganesh RA, Mangalaparthi KK, Sonpatki P, Gupta MK, Amaresha CB, Prasad K, Mariswamappa K, Pillai S, Lakshmikantha A, Shah N, Sirdeshmukh R. Identification of a Novel Splice Variant of Neural Cell Adhesion Molecule in Glioblastoma Through Proteogenomics Analysis. OMICS 2018;22:437-48. [PMID: 29927716 DOI: 10.1089/omi.2017.0220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Li Z, Chen X, Wei M, Liu G, Tian Y, Zhang X, Zhu G, Chen C, Liu J, Wang T, Lin G, Wang J, Cai G, Lv Y. Systemic Analysis of RNA Alternative Splicing Signals Related to the Prognosis for Head and Neck Squamous Cell Carcinoma. Front Oncol 2020;10:87. [PMID: 32117741 DOI: 10.3389/fonc.2020.00087] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Desterro J, Bak-Gordon P, Carmo-Fonseca M. Targeting mRNA processing as an anticancer strategy. Nat Rev Drug Discov 2020;19:112-29. [PMID: 31554928 DOI: 10.1038/s41573-019-0042-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
21 Guardia GDA, Correa BR, Araujo PR, Qiao M, Burns S, Penalva LOF, Galante PAF. Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles. NPJ Genom Med 2020;5:2. [PMID: 31969990 DOI: 10.1038/s41525-019-0108-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
22 Lan Y, Zhang J. Modulation of untranslated region alternative polyadenylation in glioma tumorigenesis. Biomedicine & Pharmacotherapy 2021;137:111416. [DOI: 10.1016/j.biopha.2021.111416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Krichevsky AM, Uhlmann EJ. Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Neurotherapeutics 2019;16:319-47. [PMID: 30644073 DOI: 10.1007/s13311-018-00702-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]